Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

L
Lam, Inez

Johns Hopkins University
PT-022 - COMPUTATIONAL SYSTEMS PHARMACOLOGY OF PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATES
Inez Lam
Favorite
Lam, Kevin

Thomas Jefferson University
PII-129 - ONDANSETRON FOR THE TREATMENT OF NEONATAL OPIOID WITHDRAWAL SYNDROME.
Kevin Lam
Favorite
Larson, Kajal

Innoviva Specialty Therapeutics, Inc
PII-035 - A BIOEQUIVALENCE AND FOOD EFFECT CLINICAL STUDY OF ZOLIFLODACIN, FIRST-IN-CLASS ORAL ANTIBIOTIC, BEING DEVELOPED FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA
Kajal Larson
Favorite
Le, Anh-Dung

U.S. Food and Drug Administration
PII-001 - APPROVED THERAPEUTIC PROTEINS WITH CHALLENGES IN CLINICAL ENDPOINTS EVALUATION WHERE PHARMACODYNAMIC BIOMARKERS MAY IMPROVE EFFICIENCY OF BIOSIMILAR DEVELOPMENT
Anh-Dung Le
Favorite
Lee, Hyoeun

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital
PII-131 - PHARMACOKINETIC PARAMETER ESTIMATION OF GENTAMICIN IN AN OBESE HEMODIALYSIS PATIENT: A CASE REPORT
Hyoeun Lee
Favorite
Lee, Sooyoun

Seoul National University Hospital
PII-107 - COMPARATIVE PHARMACOKINETICS/PHARMACODYNAMICS OF FIXED-DOSE COMBINATION OF RABEPRAZOLE/MAGNESIUM OXIDE 10/350MG (DHNP-2001A) TO THE CONVENTIONAL ENTERIC-COATED RABEPRAZOLE 10MG
Sooyoun Lee
Favorite
Lee, Sujong

Seoul National University Hospital
PII-114 - EVALUATION OF HIGH-DOSE VUTIGLABRIDIN IN HEALTHY PARTICIPANTS: SAFETY, FOOD EFFECT, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS
Sujong Lee
Favorite
Lee, Yunghon

U.S. Food and Drug Administration
PII-006 - A SNAPSHOT OF PHARMACODYNAMIC BIOMARKERS BIOANALYSIS IN 16 BLAS APPROVED FOR NEUROLOGY INDICATIONS.
Yunghon Lee
Favorite
Lennox, Ashley

Geron Corporation
PII-050 - CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
Ashley Lennox
Favorite
PII-128 - NOVEL NONLINEAR POPULATION PHARMACOKINETIC MODEL OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
Ashley Lennox
Favorite
Leonov, Vladislav

INSYSBIO UK Ltd, Edinburgh, UK
PII-014 - UNRAVELING IL9 SERUM DISTRIBUTION PATTERNS: INSIGHTS FROM THE CYTOCON DATABASE
Vladislav Leonov
Favorite
Lewis, Tamorah

The University of Toronto Temerty Faculty of Medicine
LB-024 - PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Tamorah Lewis
Favorite
Liao, Michael

Genentech
CT-011 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)
Michael Liao
Favorite
PII-052 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)
Michael Liao
Favorite
Li, Chao

AnHeart Therapeutics
PII-153 - PREDICTION OF PFS BASED ON TUMOR GROWTH INHIBITION METRICS IN HER2 POSITIVE BREAST CANCER PATIENTS FOLLOWING HER2 ADC FS-1502 TREATMENT
Chao Li
Favorite
Lindsey, Jacob

Purdue University
PII-172 - IN SILICO PREDICTION OF ION CHANNEL EFFECTS OF METHADONE LEADING TO QT INTERVAL PROLONGATION.
Jacob Lindsey
Favorite
Li, Tommy

Genmab
PII-003 - EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL.
Tommy Li
Favorite
PII-004 - MODEL-BASED REPRIMING WINDOW SELECTION FOR SUBCUTANEOUS EPCORITAMAB.
Tommy Li
Favorite
Littleton, Shana

University of Michigan - Ann Arbor
CT-009 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Shana Littleton
Favorite
PII-073 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Shana Littleton
Favorite
Liu, Guansheng

US FDA
LB-023 - PATH TO REGULATORY REVIEW OF A QUANTITATIVE SYSTEM PHARMACOLOGY (QSP) MODEL
Guansheng Liu
Favorite
Liu, Jing

Pfizer, Inc.
PII-194 - A PHASE 1 STUDY COMPARING PHARMACOKINETICS OF RIMEGEPANT 25 MG ORALLY DISINTEGRATING TABLET (ODT) PEDIATRIC FORMULATION WITH RIMEGEPANT 75 MG ODT ADULT FORMULATION, WHEN ADMINISTERED AT A SINGLE DOSE OF 75 MG UNDER FASTING CONDITIONS
Jing Liu
Favorite
Liu, Shuhan

University of Michigan
PII-059 - MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL
Shuhan Liu
Favorite
Liu, Xiaomei

Children's National Medical Center
PII-206 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY.
Xiaomei Liu
Favorite
Li, Xinnong

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
PII-168 - DEVELOPMENT OF GRAPHICAL INTERFACE IN R SHINY FOR PBPK MODEL-BASED PREDICTION AND SIMULATION OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Xinnong Li
Favorite
PT-014 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Xinnong Li
Favorite
Lovern, Mark

InSilicoTrials Technologies LLC, Stafford, USA
LB-029 - POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) ANALYSES OF MULTIPLE INTRAVENOUS INFUSIONS OF NX210C PEPTIDE IN HEALTHY ELDERLY VOLUNTEERS (HEVS)
Mark Lovern
Favorite